Publications by authors named "Michael Merker"

Claim this Profile
D
Didactic and Content Quality of Basic Life Support Videos on YouTube: Cross-Sectional Study.
Jasmina Sterz, Yvonne Beaugé, Pia Tueckmantel, Lena Bepler, Armin N Flinspach, Michael Merker

JMIR Form Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.
Laura M Moser, Catrin Heim, Sebastian E Koschade, Philipp Wendel, Süleyman Bozkurt, Michael Merker

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
Catrin Heim, Leonie Hartig, Nadine Weinelt, Laura M Moser, Emilia Salzmann-Manrique, Michael Merker

Mol Ther Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012-2021) from a University Hospital in Germany.
Leonore Purwien, Susanne Schubert-Bast, Matthias Kieslich, Michael W Ronellenfitsch, Michael Merker

CNS Drugs· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Catrin Heim, Laura M Moser, Herman Kreyenberg, Halvard B Bonig, Torsten Tonn, Michael Merker

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the First COVID Lockdown on Accident- and Injury-Related Pediatric Intensive Care Admissions in Germany-A Multicenter Study.
Nora Bruns, Lea Y Willemsen, Katharina Holtkamp, Oliver Kamp, Marcel Dudda, Michael Merker

Children (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Michael Merker, Juliane Wagner, Hermann Kreyenberg, Catrin Heim, Laura M Moser

Front Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depletion of CD45RA T cells: Advantages and disadvantages of different purification methods.
Melanie Bremm, Theresa Krastel, Claudia Cappel, Olga Zimmermann, Lisa-Marie Pfeffermann, Michael Merker

J Immunol Methods· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.
Leonie D H Gossel, Catrin Heim, Lisa-Marie Pfeffermann, Laura M Moser, Halvard B Bönig, Michael Merker

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation.
Annekathrin Heinze, Beatrice Grebe, Melanie Bremm, Sabine Huenecke, Tasleem Ah Munir, Michael Merker

Front Immunol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
Melanie Bremm, Lisa-Marie Pfeffermann, Claudia Cappel, Verena Katzki, Stephanie Erben, Michael Merker

Front Immunol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience.
Michael Merker, Michael Torsten Meister, Annekathrin Heinze, Andrea Jarisch, Jan Sörensen

Oncotarget· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.
Michael Merker, Emilia Salzmann-Manrique, Verena Katzki, Sabine Huenecke, Melanie Bremm

Biol Blood Marrow Transplant· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?
Shahrzad Bakhtiar, Emilia Salzmann-Manrique, Martin Hutter, Thomas Krenn, Matthias Duerken, Michael Merker

Bone Marrow Transplant· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk soft tissue sarcomas: results of a single-center prospective trial.
Michael Merker, Michael Torsten Meister, Eva Rettinger, Andrea Jarisch, Jan Soerensen

Bone Marrow Transplant· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.
Michael Merker, Verena Pfirrmann, Sarah Oelsner, Simone Fulda, Thomas Klingebiel

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.
Eva Rettinger, Michael Merker, Emilia Salzmann-Manrique, Hermann Kreyenberg, Thomas Krenn

Biol Blood Marrow Transplant· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy.
Eva Rettinger, Sabine Huenecke, Halvard Bonig, Michael Merker, Andrea Jarisch

Haematologica· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Verena Pfirrmann, Sarah Oelsner, Eva Rettinger, Sabine Huenecke, Halvard Bonig, Michael Merker

Cytotherapy· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
Eva Rettinger, Hermann Kreyenberg, Michael Merker, Selim Kuçi, Andre Willasch

Cytotherapy· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis